
## Castanha et al

## **Supplemental Material**




**Figure S1. Dermal myeloid cells lack evidence of proliferation following DENV-2 infection.** Immunofluorescence of skin stained with antibody to Ki67 (green) after inoculation with DENV-2 in skin pretreated with DENV-3 immune sera or naïve sera. Blue staining represents nuclei and dotted lines indicate epidermal-dermal junction. Note scattered Ki67+ cells in epidermis in both conditions, consistent with homeostatic


keratinocyte division. Scale bar 50µm.

**Table S1. Binding properties of DENV-3 and ZIKV immune serum to homologous and heterologous virus.** Mean ± SEM of IC50 values (log10) of DENV-3 and ZIKV immune serum to homologous and heterologous virus.

| Antigen | IC50±SEM        |           |
|---------|-----------------|-----------|
|         | aDENV-3         | aZIKV     |
| DENV-2  | 3.05±0.13       | 1.77±0.23 |
| DENV-3  | 3.23±0.05       | 1.52±0.24 |
| ZIKV    | $1.81 \pm 0.27$ | 2.07±0.24 |



**Figure S2.** Endpoint titers of binding IgG in DENV-3 and ZIKV immune serum to homologous and heterologous virus. Mean  $\pm$  SEM endpoint IgG titer for each data set are indicated. Dotted line represents initial serum dilution. Statistically significant differences were determined through Kruskal-Wallis test, followed by Dunn multiple comparison tests and are marked as \**p* <0.05 and \*\*\* *p* <0.0001.



**Figure S3. Blockage of CD32 and/or CD64 does not affect DENV infection in epidermis.** Quantification of the density of NS3-expressing cells in epidermis after inoculation with 10<sup>3</sup> FFU of DENV-2 in skin pretreated with neutralizing antibodies to CD32 and/or CD64 combined with a 1:40 dilution of naïve or DENV-3 immune sera. Each symbol represents a different donor and horizontal lines represent means.